Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer
Table 4
Univariable and multivariable Cox regression analyses for the prediction of PSA progression-free survival in 124 CRPC patients treated with enzalutamide.